New findings from a Phase 3 multicenter, randomized head-to-head study comparing ustekinumab and Enbrel® for the treatment of moderate to severe psoriasis showed ustekinumab superior to Enbrel according to primary and major secondary efficacy endpoints.

Original post by Epinions Recent Content for Golf